. Levosimendan, a calcium sensitizer, increases the sensitivity of the heart to calcium but increases cardiac contractility without a rise in intracellular calcium.
In 2 separate trials, (7, 8) subdivided into 4 classic (a, b, bII, g) and 4 novel (d, ε, q, h) isotypes, the latter of which can be activated by diacylglycerol alone. A third group, the atypicals (PKCl/i and PKCz), requires neither calcium nor diacylglycerol for activation. Each of the kinases can be found in the same tissue and activated by the same stimuli. Drug development for these kinases has progressed slowly due to the off-target effects of the drugs, the plasticity of each enzyme in multiple signaling cascades, and the importance and ubiquity of each isoform in different cells (12) . In addition, the translation of preclinical or animal models to clinical events has been difficult due to the differential expression of these isoforms from mouse to man (13) .
As such, only a single drug, ruboxistaurin, has pro- However, the dobutamine doses began at 5 mg/kg/min with the ability to escalate to 40 mg/kg/min (8) .
Mortality was greater in levosimendan than in placebo subjects, but there was a nonsignificant trend to improved survival compared to dobutamine subjects (8).
Mechanistically, PKCa and -b can change contractility in rodent models (20, 21) . Since the epitopes for a PKCa Thr 638 and PKC bII Thr 641 are very similar Furthermore, it is unknown whether the reduction in ventricular volume is a persistent finding, and neither is the mechanism whereby the ventricular volume is altered is addressed further in the study. We have learned from human studies with ADHF that even 24
to 48 h of continuous intravenous administration of positive inotropic therapy is unlikely to engender prolonged benefit in ADHF (25) .
Since the use of foxglove in the 1700s (26) , a drug that may enhance contractility of the heart and improve outcome in HFrEF and ADHF has been the holy grail with a number of unfulfilled promises (1, 8) .
Similarly, drug therapy, using inhibition of PKC, has been littered with failures since the discovery of the enzyme family 40 years ago. 
